In a report issued on August 7, Gena Wang from Barclays maintained a Sell rating on Halozyme (HALO), with a price target of $17. The company’s shares closed on Friday at $16.03.
According to TipRanks.com, Wang is a 5-star analyst with an average return of 18.3% and a 50.6% success rate. Wang covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical, Inc., Ionis Pharmaceuticals Inc, and Crispr Therapeutics AG.
The word on The Street in general, suggests a Hold analyst consensus rating for Halozyme with a $22 average price target.
See today’s analyst top recommended stocks >>
Based on Halozyme’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $14.62 million. In comparison, last year the company had a GAAP net loss of $22.89 million.
Based on the recent corporate insider activity of 29 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Halozyme Therapeutics, Inc. is a biopharmaceutical company, which engages in research, development & commercialization of human enzymes and drug candidates. It focuses on novel oncology therapies that target the tumor microenvironment. Its products include PEGPH20, HTI-1511, PEG-ADA2, and HYLENEX recombinant.
